These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30656237)

  • 21. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
    Mekonnen F; Tessema B; Moges F; Gelaw A; Eshetie S; Kumera G
    BMC Infect Dis; 2015 Oct; 15():461. PubMed ID: 26503269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. History of Pulmonary Tuberculosis.
    Pezzella AT
    Thorac Surg Clin; 2019 Feb; 29(1):1-17. PubMed ID: 30454916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.
    Ormerod LP
    Br Med Bull; 2005; 73-74():17-24. PubMed ID: 15956357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007.
    Devaux I; Manissero D; Fernandez de la Hoz K; Kremer K; van Soolingen D;
    Euro Surveill; 2010 Mar; 15(11):. PubMed ID: 20338144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis among migrant populations in the European Union and the European Economic Area.
    Odone A; Tillmann T; Sandgren A; Williams G; Rechel B; Ingleby D; Noori T; Mladovsky P; McKee M
    Eur J Public Health; 2015 Jun; 25(3):506-12. PubMed ID: 25500265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011.
    Sandgren A; Hollo V; van der Werf MJ
    Euro Surveill; 2013 Mar; 18(12):. PubMed ID: 23557943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia.
    Demile B; Zenebu A; Shewaye H; Xia S; Guadie A
    BMC Infect Dis; 2018 May; 18(1):249. PubMed ID: 29855354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug-resistant tuberculosis in Lithuania - Still a long way ahead.
    Musteikienė G; Miliauskas S; Sakalauskas R; Vitkauskienė A; Žemaitis M
    Medicina (Kaunas); 2016; 52(2):69-78. PubMed ID: 27170479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis.
    Yew WW
    Chemotherapy; 1999; 45 Suppl 2():26-33. PubMed ID: 10449895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug resistant tuberculosis].
    Zwolska Z; Augustynowicz-Kopeć E
    Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensively drug-resistant tuberculosis in california, 1993-2006.
    Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
    Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union.
    Portaels F; Rigouts L; Bastian I
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):582-8. PubMed ID: 10423220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberculosis in Iran: a historical overview from al-Tabari, Rhazes, Avicenna and Jorjani to Abolhassan Ziyā-Zarifi. Old and new pioneers in the fight against tuberculosis: challenges, pitfalls and hopes.
    Behzadifar M; Martini M; Behzadifar M; Bragazzi NL
    J Prev Med Hyg; 2020 Mar; 61(1 Suppl 1):E13-E15. PubMed ID: 32529099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tuberculosis in Poland in 2013.
    Korzeniewska-Koseła M
    Przegl Epidemiol; 2015; 69(2):277-82, 389-93. PubMed ID: 26233087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TB management in the European Union/European Economic Area: a multi-centre survey.
    Sotgiu G; Rosales-Klintz S; Centis R; D'Ambrosio L; Verduin R; Correia AM; Cirule A; Duarte R; Gadzheva B; Gualano G; Kunst H; Palmieri F; Riekstina V; Stefanova D; Tiberi S; van der Werf MJ; Migliori GB
    Int J Tuberc Lung Dis; 2021 Feb; 25(2):126-133. PubMed ID: 33656424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis in Poland in 2014.
    Korzeniewska-Koseła M
    Przegl Epidemiol; 2016; 70(2):261-272. PubMed ID: 27824436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.